| Ticker | DAWN |
|---|---|
| ISIN | US23954D1090 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated pr...
El precio actual de Day One Biopharmaceuticals, Inc. (DAWN) es de 21,53 , con una variación del 0,00%.
Day One Biopharmaceuticals, Inc. opera en el sector Healthcare, industria Biotechnology.